Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: KanadaFázis nélkül

ALLIANCE AVIV: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve in Failing Aortic Bioprosthetic Valves

A legfontosabb adatok

Ki végzi
Edwards Lifesciences
Hol
Hamilton, Québec és Vancouver (Kanada)Mind a 3 helyszín megnézéseMég 1 másik országban, 34 helyszínen
Azonosító
Állapot
Toboroz
Résztvevők
200 fő, tervezett
Kezdés
2023. nov. 22.
Várható befejezés
2039. dec.
A vizsgálat típusa
Beavatkozással járó, 2 csoport
A vizsgált kezelések
  • SAPIEN X4/X4S THV
A regiszteradat frissítve
2026. október 7.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for people whose earlier biological (tissue) aortic heart valve is failing and who are at high or greater risk for surgery. They get a new SAPIEN X4/X4S valve placed through a tube in a blood vessel.

Nem
All sexes can join.
A betegség stádiuma
The failing aortic tissue valve has at least moderate narrowing and/or at least moderate leaking. Heart failure symptoms of NYHA class II or higher. The heart team agrees surgery risk is high or greater.
Korábbi kezelés
Must already have a biological aortic replacement valve, put in by surgery or through a catheter, with a size that fits the SAPIEN X4 valve. No surgery or catheter procedure in the 30 days before the study procedure; a pacemaker or defibrillator implant is allowed.

A részvétel fő kizáró okai

  • Leaking around the failing valve, or a valve that is loose or damaged
  • Left heart pumping strength (ejection fraction) below 20%
  • Heart attack within 30 days, or stroke or mini-stroke within 90 days
  • Kidney failure or being on kidney replacement therapy, such as dialysis
  • Pregnant or breastfeeding, or expected to live less than 24 months

A regiszter feltételei, szó szerint

Mind a 37 feltétel megnézéseKevesebb

Ki vehet részt

  • Failing aortic bioprosthetic valve demonstrating ≥ moderate stenosis and/or ≥ moderate insufficiency
  • Bioprosthetic valve size suitable for SAPIEN X4 THV
  • NYHA functional class ≥ II
  • Heart Team agrees the subject is at high or greater surgical risk
  • The subject has been informed of the nature of the study, agrees to its provisions and has provided written informed consent

Ki nem vehet részt

  • Surgical or transcatheter valve in the mitral position
  • Myocardial infarction within 30 days prior to the study procedure
  • Subjects with planned concomitant ablation for atrial fibrillation
  • Any surgical or transcatheter procedure within 30 days prior to the study procedure. Implantation of a permanent pacemaker or implantable cardioverter defibrillator is not considered an exclusion
  • Any planned surgical or transcatheter intervention to be performed within 30 days following the study procedure
  • Endocarditis within 180 days prior to the study procedure
  • Stroke, transient ischemic attack or neurological signs and symptoms attributed to carotid or vertebrobasilar disease within 90 days prior to the study procedure
  • Hemodynamic or respiratory instability requiring inotropic or mechanical support within 30 days prior to the study procedure
  • Inability to tolerate or condition precluding treatment with antithrombotic therapy
  • Absolute contraindications or allergy to iodinated contrast that cannot be adequately treated with premedication
  • Active SARS-CoV-2 infection or previously diagnosed with COVID-19 with sequelae that could confound endpoint assessments
  • Participating in another investigational drug or device study that has not reached its primary endpoint
  • Cardiac imaging evidence of intracardiac mass, thrombus or vegetation
  • Clinically significant coronary artery disease requiring revascularization
  • Renal insufficiency and/or renal replacement therapy
  • Hypercoagulable state or other condition that increases risk of thrombosis
  • Left ventricular ejection fraction < 20%
  • Anatomical characteristics that would preclude safe femoral placement of the introducer sheath or safe passage of the delivery system
  • Failing valve has moderate or severe paravalvular regurgitation
  • Failing valve is unstable, rocking, or not structurally intact
  • Known severe patient-prosthesis mismatch or bioprosthetic valve with residual mean gradient > 20 mmHg at the end of the index procedure for implantation of the original valve
  • Increased risk of THV embolization
  • Severe mitral regurgitation (> 3+) or ≥ moderate mitral stenosis
  • Need for mitral, tricuspid or pulmonic valve intervention within the next 12 months
  • Increased risk of coronary artery obstruction after THV implantation
  • Hypertrophic cardiomyopathy with subvalvular obstruction
  • Leukopenia, anemia, thrombocytopenia
  • Subject refuses blood products
  • Body mass index > 50 kg/m2
  • Estimated life expectancy < 24 months
  • Female who is pregnant or lactating
  • Subject considered to be part of a vulnerable population

Helyszínek itt: Kanada

Még 1 másik országban, 34 helyszínen

  • Hamilton Health SciencesHamilton, KanadaContact: Edwards THV Clinical AffairsRésztvevőt keres
  • Institut Universitaire de Cardiologie et de Pneumologie de Quebec-Université LavalQuébec, KanadaContact: Edwards THV Clinical AffairsRésztvevőt keres
  • St. Paul's Hospital, VancouverVancouver, KanadaContact: Edwards THV Clinical AffairsRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

The objective of this study is to establish the safety and effectiveness of the Edwards SAPIEN X4/X4S Transcatheter Heart Valve (THV) in subjects who are at high or greater risk with a failing aortic bioprosthetic valve.

A vizsgálat 2 csoportja

  • Transcatheter Aortic Valve Replacement (TAVR) - Surgical ValveA vizsgált kezelés

    TAVR implant in subjects with a failing aortic surgical valve.

    Kezelés: SAPIEN X4/X4S THV

  • Transcatheter Aortic Valve Replacement (TAVR) - THVA vizsgált kezelés

    TAVR implant in subjects with a failing aortic transcatheter heart valve (THV).

    Kezelés: SAPIEN X4/X4S THV

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Safety and Effectiveness of Balloon-Expandable Bioprosthetic SAPIEN X4 Transcatheter Heart Valve in Failing Aortic Bioprosthetic Valves
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
A regiszteradat frissítve
2026. október 7.